Natco Pharma shares surge 5% after US FDA's tentative nod Olaparib tablets

Natco Pharma shares surged 5 percent after the company received US FDA tentative approval for Olaparib Tablets in 100 mg and 150 mg strengths, bioequivalent to AstraZeneca's Lynparza, with marketing partner Alembic Pharmaceuticals handling US distribution. The drug has estimated US sales of around USD 1.4 billion for the 12 months ended March 2026, though final approval awaits resolution of ongoing Para IV patent litigation.